Interim results are in line with the detailed trading statement issued in July; revenue fell to £2.0m but, following significant cost cutting outlined in the 2018 strategy, EBITDA became positive at £0.2m with £0.6m of cash on the balance sheet. The Group has been more selective with its direct selling activities in the US such that, whilst volumes fell, average prices increased, and revenue only fell from £0.8m to £0.7m. In our view, the price traction demonstra
23 Sep 2019
Interim results
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Interim results
Deltex Medical Group plc (DEMG:LON) | 0.1 0 0.0% | Mkt Cap: 2.37m
- Published:
23 Sep 2019 -
Author:
Andrew Simms -
Pages:
2
Interim results are in line with the detailed trading statement issued in July; revenue fell to £2.0m but, following significant cost cutting outlined in the 2018 strategy, EBITDA became positive at £0.2m with £0.6m of cash on the balance sheet. The Group has been more selective with its direct selling activities in the US such that, whilst volumes fell, average prices increased, and revenue only fell from £0.8m to £0.7m. In our view, the price traction demonstra